<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131700</url>
  </required_header>
  <id_info>
    <org_study_id>RPH001BEV01</org_study_id>
    <nct_id>NCT03131700</nct_id>
  </id_info>
  <brief_title>Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator</brief_title>
  <official_title>Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRPHARM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRPHARM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this to assess pharmacokinetic bioequivalence between two bevacizumab
      products, RPH-001 (TRPHARM) and EU sourced Avastin® (Roche), after single IV administration
      at 5 mg/kg fixed dose.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Decision of the Sponsor
  </why_stopped>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under concentration-time curve from time zero to the last sampling time</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>Area Under the Curve - AUC(0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under concentration-time curve from time zero to infinity</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>Area Under the Curve - AUC(0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration-time profiles</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>RPH-001 and Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>RPH-001 and Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t½)</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>RPH-001 and Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>RPH-001 and Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz)</measure>
    <time_frame>Until 100 days after administration</time_frame>
    <description>RPH-001 and Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, frequency, severity and relationship to study drug of recorded adverse events</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug-antibody (ADA)</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody (NAb)</measure>
    <time_frame>Until 100 days after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RPH-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU sourced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of Avastin® will be administered (IV) 5 mg/kg dose .</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RPH001</intervention_name>
    <description>Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.</description>
    <arm_group_label>RPH-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avastin®</intervention_name>
    <description>R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.</description>
    <arm_group_label>EU sourced Avastin®</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 18 to 55 years inclusive.

          -  Adult healthy male subjects between 18.0 and 30.0 kg/m2 body mass index (inclusive)
             and body weight ≥ 60 kg and ≤ 100 kg (inclusive).

        Exclusion Criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,
             osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or
             signs of acute illness.

          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,
             anti hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and
             2 antibodies (anti-HIV1 and anti HIV2 Ab).

          -  Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, opiates).

          -  Positive alcohol test at screening or baseline visits
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zafer Sezer, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKUM</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RPH101</keyword>
  <keyword>RPH-101</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

